- Home
- TORO vs CELU Comparison
TORO vs CELU Comparison
Compare TORO & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- CELU
- Stock Information
- Founded
- TORO 2022
- CELU 2016
- Country
- TORO Cyprus
- CELU United States
- Employees
- TORO N/A
- CELU N/A
- Industry
- TORO Marine Transportation
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- CELU Health Care
- Exchange
- TORO Nasdaq
- CELU Nasdaq
- Market Cap
- TORO 62.4M
- CELU 64.6M
- IPO Year
- TORO N/A
- CELU N/A
- Fundamental
- Price
- TORO $2.67
- CELU $2.85
- Analyst Decision
- TORO
- CELU
- Analyst Count
- TORO 0
- CELU 0
- Target Price
- TORO N/A
- CELU N/A
- AVG Volume (30 Days)
- TORO 42.7K
- CELU 3.2M
- Earning Date
- TORO 11-12-2024
- CELU 11-07-2024
- Dividend Yield
- TORO N/A
- CELU N/A
- EPS Growth
- TORO N/A
- CELU N/A
- EPS
- TORO 0.99
- CELU N/A
- Revenue
- TORO $80,626,531.00
- CELU $42,690,000.00
- Revenue This Year
- TORO N/A
- CELU N/A
- Revenue Next Year
- TORO N/A
- CELU $233.89
- P/E Ratio
- TORO $0.97
- CELU N/A
- Revenue Growth
- TORO N/A
- CELU 182.02
- 52 Week Low
- TORO $2.50
- CELU $1.30
- 52 Week High
- TORO $6.45
- CELU $7.97
- Technical
- Relative Strength Index (RSI)
- TORO 33.33
- CELU 53.63
- Support Level
- TORO $2.50
- CELU $2.12
- Resistance Level
- TORO $2.79
- CELU $3.06
- Average True Range (ATR)
- TORO 0.16
- CELU 0.89
- MACD
- TORO -0.02
- CELU 0.05
- Stochastic Oscillator
- TORO 18.20
- CELU 37.96
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.